Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PTHS

Pelthos Therapeutics Inc

Feb 09 • 04:00PM ET

22.08

-0.91 -3.96 %

Healthcare • Biotechnology • USA • AMEX

Peers: VRTX BMRN SRPT BLUE ALNY IONS NBIX AMGN GILD REGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	12.57%	Shs Outstand	3.09M	Perf Week	-12.73%
Market Cap	71.44M	Forward P/E	-	EPS next Y	-	Insider Trans	-2.40%	Shs Float	2.83M	Perf Month	-21.31%
Enterprise Value	60.67M	PEG	-	EPS next Q	-3.26	Inst Own	21.19%	Short Float	2.22%	Perf Quarter	-40.99%
Income	-	P/S	-	EPS this Y	-	Inst Trans	15.34%	Short Ratio	2.70	Perf Half Y	15.97%
Sales	-	P/B	1.17	EPS next Y	-	ROA	-	Short Interest	0.06M	Perf YTD	-28.77%
Book/sh	18.85	P/C	5.01	EPS next 5Y	-	ROE	-	52W High	54.29 -59.33%	Perf Year	39.75%
Cash/sh	4.40	P/FCF	-	EPS past 3/5Y	-140.00% -87.88%	ROIC	-	52W Low	9.00 145.33%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.78% 6.84%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-160.85%	Oper. Margin	-	ATR (14)	1.81	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.37	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.98	EPS Q/Q	-72.86%	SMA20	-8.87%	Beta	4.12	Target Price	60.40
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	-12.98%	Rel Volume	0.23	Prev Close	22.99
Employees	4	LT Debt/Eq	0.05	Earnings	Nov 13 BMO	SMA200	-3.47%	Avg Volume	23.22K	Price	22.08
IPO	Feb 16, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	-821.74% 68.72%	Trades		Volume	5,397	Change	-3.96%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-03-25	Initiated	Lake Street	Buy	$50
Dec-03-25	Initiated	H.C. Wainwright	Buy	$60
Nov-25-25	Initiated	Roth Capital	Buy	$57
Sep-02-25	Initiated	Oppenheimer	Outperform	$50

Jan-13-26 08:30AM	Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance (GlobeNewswire)
Jan-05-26 07:30AM	Pelthos Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice (GlobeNewswire) -9.03%
Dec-23-25 05:57PM	Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn (GlobeNewswire)
Dec-04-25 07:00AM	Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI (berdazimer) Topical Gel, 10.3% (GlobeNewswire)
Dec-02-25 08:00AM	Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
06:45AM	Loading…
Nov-13-25 06:45AM	Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results (GlobeNewswire) -7.27%
Nov-07-25 08:00AM	Pelthos Therapeutics Acquires Xepi (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing (GlobeNewswire) -8.07%
Nov-05-25 08:00AM	Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025 (GlobeNewswire) +6.47%
Oct-09-25 08:00AM	Pelthos Therapeutics Launches Moms Against Molluscum Movement to Unite Families Affected by Molluscum Contagiosum (GlobeNewswire) -7.89%
Sep-08-25 08:30AM	Pelthos Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire) +13.96%
Sep-02-25 08:00AM	Pelthos Therapeutics to Participate in the 2025 Wells Fargo Healthcare Conference (GlobeNewswire) -5.03%
Aug-18-25 08:00AM	Pelthos Therapeutics Reports Second Quarter 2025 Financial Results for Legacy Operations and Provides Business Update (GlobeNewswire)
Jul-10-25 08:00AM	Pelthos Therapeutics Launches ZELSUVMI (berdazimer) Topical Gel 10.3%, the First and Only FDA-Approved At-Home Treatment for Molluscum Contagiosum (GlobeNewswire) +60.78%
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire) +22.22%
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)

Pelthos Therapeutics, Inc. engages in the provision of therapeutic products. It produces products under its proprietary nitic oxide-based technology platform Nitricil. Its main product is a topical gel for the treatment of molluscum contagiosum. The company was founded on March 19, 2021 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pauls Matthew	Director	Oct 02 '25	Option Exercise	0.00	2,123	0	10,616	Dec 12 05:01 PM
Pauls Matthew	Director	Jul 02 '25	Option Exercise	0.00	8,493	0	8,493	Dec 12 05:01 PM
Friedberg Ezra M	Director	Nov 25 '25	Sale	28.03	10,000	280,280	30,000	Nov 26 12:37 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTHS

Pelthos Therapeutics Inc

Upgrade your FINVIZ experience